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A key function of human eosinophils is to secrete cytokines, chemokines and cationic
proteins, trafficking, and releasing these mediators for roles in inflammation and
other immune responses. Eosinophil activation leads to secretion of pre-synthesized
granule-stored mediators through different mechanisms, but the ability of eosinophils
to secrete extracellular vesicles (EVs), very small vesicles with preserved membrane
topology, is still poorly understood. In the present work, we sought to identify and
characterize EVs released from human eosinophils during different conditions: after a
culturing period or after isolation and stimulation with inflammatory stimuli, which are
known to induce eosinophil activation and secretion: CCL11 (eotaxin-1) and tumor
necrosis factor alpha (TNF-α). EV production was investigated by nanoscale flow
cytometry, conventional transmission electron microscopy (TEM) and pre-embedding
immunonanogold EM. The tetraspanins CD63 and CD9 were used as EV biomarkers
for both flow cytometry and ultrastructural immunolabeling. Nanoscale flow cytometry
showed that human eosinophils produce EVs in culture and that a population of EVs
expressed detectable CD9, while CD63 was not consistently detected.When eosinophils
were stimulated immediately after isolation and analyzed by TEM, EVs were clearly
identified as microvesicles (MVs) outwardly budding off the plasma membrane. Both
CCL11 and TNF-α induced significant increases of MVs compared to unstimulated cells.
TNF-α induced amplified release of MVs more than CCL11. Eosinophil MV diameters
varied from 20 to 1000 nm. Immunonanogold EM revealed clear immunolabeling for
CD63 and CD9 on eosinophil MVs, although not all MVs were labeled. Altogether,
we identified, for the first time, that human eosinophils secrete MVs and that this
production increases in response to inflammatory stimuli. This is important to understand
the complex secretory activities of eosinophils underlying immune responses. The
contribution of the eosinophil-derived MVs to the regulation of immune responses awaits
further investigation.
Keywords: cell secretion, inflammation, CCL11 (eotaxin-1), tumor necrosis factor alpha (TNF-α), tetraspanins,
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INTRODUCTION
Eosinophils, leukocytes of the innate immune system that are
involved in the pathogenesis of asthma, allergies, and other
diseases as well as other ongoing homeostatic roles in tissues,
have a remarkable ability to secrete specific proteins in response
to inflammatory stimuli. A plethora of mediators are stored
as preformed molecules within eosinophil specific (secretory)
granules, the singular granule population in the cytoplasm of
these cells such as distinct cationic proteins and cytokines
(reviewed in Spencer et al., 2014).
Some major mechanisms leading to secretion of granule-
derived immune mediators have been well-characterized in
human eosinophils. In response to cell activation, granules can
fuse with the plasmamembrane in order to secrete their contents,
but the most frequent mechanism for the delivery of eosinophil
mediators involve vesicular carriers, which recruit cargos directly
from secretory granules, a secretory process termed piecemeal
degranulation (reviewed in Melo and Weller, 2010; Melo et al.,
2013a; Spencer et al., 2014). While the study of eosinophil
degranulation processes has received great attention in the last
decade, the ability of eosinophils to secrete membrane vesicles,
collectively termed extracellular vesicles (EVs), remains to be
explored.
Various names, including exosomes and microvesicles
(MVs)/microparticles, have been given to secreted EVs. While
the term exosomes is used for referring to a population of
EVs, which are released from cells when multivesicular bodies
(MVBs) fuse with the plasma membrane, the term MVs has
been generally used for EVs formed by budding and shedding
of the plasma membrane (reviewed in van der Pol et al., 2012;
Twu and Johnson, 2014; Lawson et al., 2016). Recently, it was
demonstrated that human eosinophils secrete exosomes in
culture cell conditions and that this type of EV is increased in
asthmatic patients, which links EVs with eosinophil activation
(Mazzeo et al., 2015). However, the functions of EVs secreted
by immune cells during inflammatory responses are still poorly
understood. It is believed that these vesicles can act as carriers of
cell-cell communication mediators such as cytokines and lipid
mediators, and potentially contribute to inflammation (reviewed
in Buzas et al., 2014). Moreover, a potential immunomodulatory
role for treating or preventing inflammatory disorders has been
attributed to EVs (Buzas et al., 2014).
EVs secreted by cells can be detected by nanoscale flow
cytometric methods, which identify and sort submicron particles
(Danielson et al., 2016) and transmission electron microscopy
(TEM), which enables unambiguous visualization of EVs
(reviewed in Lawson et al., 2016). EM is thus considered an
essential technique to characterize EVs and to distinguish them
from non-membranous particles of similar size, as endorsed by
the International Society for EVs in an effort to provide minimal
requirements for EV definition (Lötvall et al., 2014).
Our group has been using different EM techniques, including
conventional TEM and immunonanogold EM, to understand
mechanisms of vesicular trafficking and release of immune
mediators from human eosinophils activated by inflammatory
stimuli (Melo et al., 2005a,b, 2008a, 2009, 2010; Spencer et al.,
2006; Carmo et al., 2015). By studying the ultrastructure of
human eosinophils isolated from the peripheral blood, we
noticed the presence of EVs budding from the cell surface when
the cells were kept alive in medium (Figure 1).
In the present work, we sought to identify and characterize
EVs released from human eosinophils during different
conditions: in culture and after stimulation with two distinct
agonist “inflammatory” stimuli, which are known to induce
eosinophil activation and secretion: the chemokine, CCL11
(eotaxin-1), and the cytokine, tumor necrosis factor alpha
(TNF-α; Egesten et al., 1998; Bandeira-Melo et al., 2001, 2003;
Liu et al., 2007; Spencer et al., 2009). In recent work, we showed
that these stimuli trigger increased formation of intracellular
transport vesicles in association with distinct processes of
eosinophil secretion (Carmo et al., 2016). We wondered if
both stimuli are also able to influence the biogenesis of EVs.
By performing a comprehensive study, using nanoscale flow
cytometry, conventional TEM and immunonanogold labeling
for CD63 and CD9, we demonstrate that human eosinophils
produce EVs, which were clearly characterized as MVs, and
that this production is increased in response to both CCL11
and TNF-α, identifying eosinophil EV genesis as a secretory
mechanism with eosinophil-mediated immune responses.
MATERIALS AND METHODS
Eosinophil Isolation, Stimulation, and
Viability
Granulocytes were isolated from peripheral blood of allergic
or healthy donors. Eosinophils were enriched and purified
by negative selection as previously described (StemSepTM,
StemCell Technologies, Seattle WA; Miltenyi Biotec, Auburn,
CA; Bandeira-Melo et al., 2000; Akuthota et al., 2014). The
hypotonic red blood cell (RBC) lysis was omitted to avoid any
potential for RBC lysis to affect eosinophil function. Eosinophil
viability and purity were >99% as determined by ethidium
bromide (Molecular Probes, Life Technologies, Carlsbad, CA)
incorporation and cytocentrifuged smears stained with HEMA 3
stain kit (Fisher Scientific, Medford, MA), respectively. Purified
eosinophils (106 cells/mL) were stimulated with TNF-α (200
ng/mL; R&D Systems, Minneapolis, MN) or recombinant human
CCL11 (100 ng/mL; R&D Systems), in RPMI-1640 medium plus
0.1% ovalbumin (OVA; Sigma, St. Louis, MO, USA), or medium
alone at 37◦C, for 1 h as before (Carmo et al., 2016).
Ethics Statement
Written informed consent was obtained from donors in
accordance with the Declaration of Helsinki, and Institutional
Review Board (IRB) approval was obtained from the Beth Israel
Deaconess Medical Center Committee on Clinical Investigation
(Boston, MA, USA).
Antibody Reagents
Mouse anti-human IgG1 CD63 (clone H5C6, catalog number
556019, 5 µg/mL, BD-Pharmingen, San Diego, CA), mouse
anti-human CD9 (clone 209306; R&D Systems, 10 µg/mL,
Minneapolis, MN) and irrelevant isotype control monoclonal
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FIGURE 1 | TEM reveals production of MVs by human eosinophils. (A) A representative micrograph of a human eosinophil documents several MVs (highlighted
in blue in Ai) budding directly from the plasma membrane. Eosinophil specific granules (Gr), the singular population of secretory granules in the cytoplasm, show
lucencies in their granule cores, indicative of cell activation. Two lipid bodies (LB), which typically appear as very electron-dense organelles in eosinophils, are seen in
the cell periphery. Eosinophils were isolated from the peripheral blood from healthy donors by negative selection, kept in medium during 1 h, immediately fixed while
still in suspension and processed for conventional TEM. N, nucleus.
antibodies (mAbs) were used for electron microscopy
immunodetection studies. The secondary Ab for immunoEM
was an affinity-purified goat anti-mouse Fab fragment conjugated
to 1.4 nm gold particles (1:100, Nanogold, Nanoprobes, Stony
Brook, NY). FITC-conjugated mouse anti-human IgG1 CD63
(clone H5C6, Biolegend, San Diego, CA), FITC-conjugated
mouse anti-human IgG1 CD9 (clone HI9a, Biolegend),
and irrelevant FITC-conjugated isotype control antibodies
were used for nanoscale flow cytometry or regular flow
cytometry.
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Nanoscale Flow Cytometry
Human eosinophils were incubated for 4 days in RPMI-1640
with 5% FBS with 10 ng/mL IL-5 and 1 ng/mL of GM-CSF
to allow for EV accumulation in the culture supernatant. Due
to the presence of FBS, culture medium was depleted of EVs
by ultracentrifugation prior to use. Supernatants were depleted
of eosinophils and debris with successive centrifugation at 300
× g, 5600 × g, and 11,000 × g. EVs were then isolated by
ultracentrifugation at 100,000 × g for 1 h. EV-depleted culture
medium without cells present subjected to the same protocol
served as a negative control. Prior to nanoscale flow cytometry,
some samples were incubated with FITC-conjugated anti-CD9
antibody or FITC-conjugated anti-CD63 antibody. Nanoscale
flow cytometry was performed as previously described using
a Beckman Coulter MoFlo AstriosEQ modified to optimize
detection of small particles down to 200 nm in diameter
(Danielson et al., 2016). Control Latex Beads were obtained from
Beckman Coulter. Electronic noise was gated out during analysis
using the signal generated by phosphate buffered saline alone as
a reference.
Flow Cytometry for CD63 in Entire Cells
For CD63 detection in human eosinophils by regular flow
cytometry, cells were incubated 1:25 in relevant antibody or
isotype control for 25 min at 4◦C. Flow cytometry for CD63
was performed using a BD Accuri Flow Cytometer. Data were
analyzed using FlowJo (TreeStar, Ashland, OR, USA).
Conventional TEM
For conventional TEM, isolated eosinophils were prepared as
before (Melo et al., 2005a, 2009). Cells were fixed in a mixture
of freshly prepared aldehydes [1% paraformaldehyde (PFO) and
1.25% glutaraldehyde] in 0.1 M sodium cacodylate buffer (final
concentration) for 1 h at RT, embedded in 2% agar and kept at
4◦C for further processing. Agar pellets containing eosinophils
were post-fixed in 1% osmium tetroxide in sym-collidine buffer,
pH 7.4, for 2 h at RT. After washing with sodium maleate buffer,
pH 5.2, pellets were stained en bloc in 2% uranyl acetate in
0.05 M sodium maleate buffer, pH 6.0 for 2 h at RT and washed
in the same buffer as before prior to dehydration in graded
ethanols and infiltration and embedding with a propylene oxide-
Epon sequence (Eponate 12 Resin; Ted Pella, Redding, CA).
Sections were mounted on uncoated 200-mesh copper grids
(Ted Pella) before staining with lead citrate and viewed with a
transmission electron microscope (CM 10; Philips, Eindhoven,
The Netherlands) at 60 KV.
Cell Preparation for Immunonanogold EM
For immunoEM, purified eosinophils were immediately fixed in
fresh 4% PFO in PBS, pH 7.4 (Melo et al., 2014). Cells were
fixed for 30 min at RT, washed in PBS and centrifuged at 1500 g
for 1min. Samples were then resuspended in molten 2% agar
in PBS and quickly recentrifuged. Pellets were immersed in 30%
sucrose in PBS overnight at 4◦C, embedded in OCT compound
(Miles, Elkhart, IN), and stored in −180◦C liquid nitrogen for
subsequent use.
Pre-embedding Immunonanogold EM
As detailed before (Melo et al., 2005b, 2009; Dias et al., 2014),
pre-embedding immunolabeling was carried out before standard
EM processing (post-fixation, dehydration, infiltration, resin
embedding and resin sectioning). All labeling steps were carried
out at RT as before (Melo et al., 2014) as follows: (a) one
wash in 0.02M PBS, pH 7.6, 5 min; (b) immersion in 50mM
glycine in 0.02M PBS, pH 7.4, 10min; (c) incubation in a
mixture of PBS and BSA (PBS-BSA buffer; 0.02M PBS plus 1%
BSA) containing 0.1% gelatin (20min) followed by PBS-BSA
plus 10% normal goat serum (NGS; 30 min)—(this step is
crucial to block non-specific Ab binding sites); (d) incubation
with primary Ab (1 h); (e) blocking with PBS-BSA plus NGS
(30min); (f) incubation with secondary Ab (1 h); (g) washing
in PBS-BSA (three times of 5min each); (h) post-fixation in
1% glutaraldehyde (10min); (i) five washings in distilled water;
(j) incubation with HQ silver enhancement kit (Nanoprobes)
in a dark room according to the manufacturer’s instructions
(10min). This step enables a nucleation of silver ions around gold
particles. These ions precipitate as silver metal and the particles
grow in size facilitating observation under TEM); (k) three
washings in distilled water; (l) immersion in freshly prepared 5%
sodium thiosulfate (5min); (m) post-fixation with 1% osmium
tetroxide in distilled water (10min); (n) staining with 2% uranyl
acetate in distilled water (5min); (o) embedding in Eponate
(Eponate 12 Resin; Ted Pella); (p) after polymerization at 60◦C
for 16 h, embedding was performed by inverting eponate-filled
plastic capsules over the slide-attached tissue sections; and (q)
separation of eponate blocks from glass slides by brief immersion
in liquid nitrogen. Thin sections were cut using a diamond
knife on an ultramicrotome (Leica). Sections were mounted on
uncoated 200-mesh copper grids (Ted Pella) before staining with
lead citrate and viewed with a transmission electron microscope
(CM 10; Philips) at 60 kV. Two controls were performed:
(1) primary Ab was replaced by an irrelevant Ab, and (2) primary
Ab was omitted. Electron micrographs were randomly taken
at different magnifications to study the entire cell profile and
subcellular features.
Quantitative EM Analysis
For quantification studies by conventional TEM (enumeration
of the total number of EVs and MVBs), electron micrographs
of cell sections were randomly taken from unstimulated and
stimulated eosinophils. Electron micrographs were taken by an
operator blind to EV identification. A total of 110 electron
micrographs (39 from unstimulated, 37 from CCL11- and 34
from TNF-α-stimulated eosinophils) and 516 EVs (55 from
unstimulated, 187 from CCL11- and 274 from TNF-α-stimulated
eosinophils) were counted. Then, the diameters of EVs were
measured and grouped in different ranges (20–100, 100–200,
200–300, 300–1000 nm). The presence of typical MVBs was
investigated in all electron micrographs. These analyses were
done in clear cross-cell sections exhibiting the entire eosinophil
cell profile, intact plasma membranes and nuclei. EVs were
morphologically defined as intact, small round vesicles, delimited
by a membrane unit, which is seen by TEM as a typical
trilaminar structure, in process of outward budding from
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the plasma membrane or closely associated with the cell
surface.
For immunonanogold EM studies, a total of 69 electron
micrographs randomly taken from unstimulated and stimulated
eosinophils were evaluated for CD63 and CD9 labeling. These
analyses were done in clear cross-cell sections exhibiting the
entire eosinophil cell profile, intact plasma membranes, and
nuclei.
All quantitative studies were performed using the Image J
software (National Institutes of Health, Bethesda, MD).
Protein Electrophoresis of EVs
For protein electrophoresis of EVs, culture supernatants of
primary human eosinophils were collected and centrifuged as
they were for nanoscale flow cytometry. Culture supernatant
from an eosinophilic leukemia cell line (Eol-1, Sigma-Aldrich)
was also collected and centrifuged. Lithium dodecyl sulfate
sample buffer (4X; Invitrogen) and sample reducing agent (10X)
(Invitrogen) were added at final 1X concentrations. Samples,
first heated for 7.5 min at 95◦C, were run on a 4–12% Bis-Tris
gel. Silver staining was then performed of polyacrylamide gel
(Thermo Scientific, Rockford, IL, USA) were used to develop
membranes.
Annexin V Analysis by Confocal
Microscopy and Flow Cytometry
To detect exposed phosphatidylserine, cells were stained with
annexin V (Gonzalez-Cano et al., 2010). Freshly isolated
human eosinophils were resuspended in 5% FBS RPMI-1640
medium (106 cells/mL) and stimulated, as above, at 37◦C
in 5% CO2 incubator. Annexin V-FITC (Medical and
Biological Laboratories, Nagoya, Japan) was then added to
the culture medium (1:20) and cells were viewed without
washing or fixing in an imaging chamber (Zell-kontakt,
Nörten-Hardenberg, Germany). The confocal microscopic and
differential interference contrast (DIC) images were captured
using a laser scanning confocal microscope with incubation
chamber (100x objective, Carl Zeiss LSM780, Jena, Germany).
For flow cytometry, annexin V-FITC stained cells were measured
using a flow cytometer (Cytomics FC500, Beckman Coulter,
Fullerton, CA, USA). Data were analyzed by Flowjo software.
Tunel Assay
Eosinophils stimulated as described were fixed with 4%
paraformaldehyde and stained using MEBSTAIN Apoptosis
TUNEL Kit (Medial Biological Laboratories, Nagoya, Japan)
according to the manufacturer’s instruction. Images were
captured using a fluorescence microscope (40x objective, Leica
DMI 4000B, Wetzlar, Germany).
Statistical Analyses
Comparison between groups was analyzed using Kruskal Wallis
test followed by Dunn’s test to adjust for multiple comparisons,
as appropriate. The significance level was set at P < 0.05. All tests
and graphs were performed with software Prism 6.0.1 (GraphPad
software, San Diego, CA). Data are expressed as means± SEM.
RESULTS
Human Eosinophils Release EVs
Over the last decade, our research group has been studying the
ultrastructure of human eosinophils during different conditions.
Our EM methodology, primarily developed for studying human
eosinophils isolated from the peripheral blood, includes prompt
aldehyde fixation while the cells are still in suspension, which
is important to optimal cell preservation and to capture specific
biological events in response to varied stimuli (Melo et al., 2005a,
2013b). Thus, cells kept alive in suspension either unstimulated
or agonist stimulated are immediately fixed after a determined
time, before any subsequent centrifugation procedure, which
could interfere with the cell morphology. While examining
resulting electron micrographs from different experiments, we
occasionally noticed clear shedding of small vesicles delimited
by a typical phospholipid bilayer from the eosinophil surface
(Figure 1).
We then decided to investigate whether eosinophils kept
in culture were able to release EVs. Eosinophils isolated from
the peripheral blood of healthy patients were incubated for
4 days in culture to allow EV accumulation in the culture
supernatant. EVs isolated by ultracentrifugation were evaluated
by nanoscale flow cytometry. Using standard latex beads, we first
confirmed the ability of the nanoscale flow cytometry approach
to discriminate small particles down to a size of 200 nm and
lower (Figure 2A). After gating out electronic noise, EVs derived
from human eosinophil cultures were identified (Figures 2B–D).
On staining EVs with FITC-conjugated anti-CD9 or anti-CD63
antibodies, we found that EVs, that were identifiable and
evaluated by nanoscale flow cytometry, had readily detectable
CD9 (Figure 2E). A band at 25 kD, consistent with the
presence of CD9 in these vesicles, was also detected by protein
electrophoresis (Supplementary Figure 1). CD63 expression
by eosinophil EVs was not detectable with nanoscale flow
cytometry (Figure 2F). All nanoscale flow cytometry results
were representative of four individual experiments from four
individual normal donors (Figure 2). Positive controls for CD63
are shown in Supplementary Figure 2.
EV Production by Human Eosinophils
Increases in Response to Inflammatory
Stimuli
Next, to study the phenomenon of vesicle release and detect
EVs at the cell surface, we stimulated freshly isolated eosinophils
from normal donors during 1 h with CCL11 or TNF-α, at
concentrations previously documented to induce secretion, or
medium alone (Carmo et al., 2016) and immediately processed
for conventional TEM. Then, electron micrographs randomly
taken from the thin sections by an operator blind to EV
identification and showing the entire cell profile and intact
plasma membrane were carefully examined. First, conventional
TEM revealed that EVs appeared mostly as MVs in both
unstimulated (Figure 3A) and stimulated (Figure 3B) cells, that
is, shedding directly from the plasma membrane. Typical MVs,
delimited by a phospholipid membrane, were seen in progressive
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FIGURE 2 | Identification of Eosinophil EVs by Nanoscale Flow Cytometry. (A) The ability of the AstriosEQ to discriminate sub-micrometer particles is shown
using a mixture of Control Latex Beads (200, 300, and 500 nm). (B) Flow cytometry of RPMI with FBS (EV-depleted) alone showing non-specific events and electronic
noise. Forward scatter and side scatter plotted. (C) Flow cytometry of human eosinophil EVs in RPMI with FBS (EV-depleted). Gate drawn around EV signal (FSC and
SSC plotted). (D) Gated eosinophil EVs. (E) Human eosinophil EVs CD9 expression (blue) overlaid on IgG control (red). (F) Human eosinophil CD63 expression (blue)
overlaid on IgG control (red) shows minimal detection of CD63 by nanoscale flow cytometry. Representative of four experiments from four individual donors. (G) Mean
CD9 fluorescence (p = 0.13, paired t-test). Panels (B–G) are representative of four independent experiments from four individual human donors.
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FIGURE 3 | CCL11 and TNF-α stimulation induce release of MVs by human eosinophils. (A, Ai, B, Bi, Bii) MVs are seen at the surface of both unstimulated
(A) and CCL11-stimulated (B) human eosinophils. Note in high magnification (Ai) that the phospholipid bilayer membrane, which is seen by TEM as a trilaminar
structure (arrowheads), is observed around the EVs, plasma membrane and secretory granule (Gr) delimiting membrane. (Bii) Shows in high magnification a MV in
final process of detaching from the plasma membrane (arrow). (C) Significant increases in numbers of MVs occurred after stimulation with CCL11 or TNF-α.
Eosinophils were isolated from the peripheral blood by negative selection, stimulated for 1 h, immediately fixed and processed for conventional TEM. Counts were
derived from three experiments with a total of 516 MVs counted in 110 electron micrographs randomly taken and showing the entire cell profile and nucleus (N). Data
represent mean ± S.E.M. ***P < 0.002 (CCL11 vs. unstimulated); ****P < 0.0001 (TNF-α vs. unstimulated); ##P < 0.02 (TNF-α vs. CCL11).
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outward budding of the plasma membrane (Figure 3B) and/or
completely released at cell surface (Figures 3A,B).
To quantify the number of MVs from each experimental
group, eosinophil sections showing the entire cell profile and
nucleus were evaluated (n = 110 cells), and a total of 516
MVs were counted. Eosinophil activation led to a significant
increase of MV production compared to unstimulated cells
(Figure 3C). Quantitative EM revealed that while unstimulated
cells had 1.4 ± 0.4 MVs/cell section, CCL11- and TNF-α-
stimulated cells showed 5.0 ± 0.8 (P = 0.0014) and 8.0 ± 1.0
(P < 0.0001) MVs/cell section (mean ± S.E.M), respectively
(Figure 3C), corresponding to an increase of 360% (CCL11)
and 570% (TNF-α). TNF-α induced a significant increase in the
release of MVs compared to CCL11 (P = 0.0116; Figure 3C).
Moreover, our quantitative analyses showed that just 50% of
unstimulated cells produced MVs whereas 90 and 100% of
eosinophils formed MVs in CCL11- and TNF-α-stimulated
groups, respectively (Figure 4A). Moreover, by scoring the
number of MVs, we found that in unstimulated cells, most MV-
producing cells (30%), released 1–3 MVs/cell section whereas
∼70% of cells produced 1–9 MVs and 4–21 MVs/cell section
in response to CCL11 and TNF-α stimulation, respectively
(Figure 4B).
Formation of MVs is a dynamic process and therefore
these vesicles may be observed by TEM in different stages
of budding from the plasma membrane or free at the cell
surface (Figures 3A,B, 5A). Because our TEM studies have
clearly captured this process as illustrated in Figure 5B, we
next wondered if there was any difference in the numbers
of budding/free MVs per treatment condition. Indeed, the
numbers of budding MVs were significantly higher in stimulated
compared to unstimulated cells [7.35 ± 0.98 for TNF-α- and
2.75 ± 0.44 for CCL11-stimulated groups vs. 0.64 ± 0.16
for unstimulated cells; MVs/cell section (mean ± S.E.M);
P < 0.0001; Figure 5C]. Interestingly, the number of MVs in
different degrees of budding was higher in TNF-α-stimulated
compared to CCL11-stimulated cells (Figure 5C; P < 0.0001).
Altogether, our findings reveal that two eosinophil agonist
“inflammatory” stimuli induce vesiculation and that this event
is more prominent in TNF-α- compared to CCL11-stimulated
cells, since the number of nascent MVs was significantly higher
in the TNF-α group (Figure 5C). Of note, the presence of MVBs
was detected within eosinophils from all groups (Supplementary
Figure 3). However, we did not find evidence for fusion of them
with the plasma membrane and resulting exososome release
(Supplementary Figure 3).
Ultrastructural Characterization of
Eosinophil-Secreted MVs
In addition to quantification studies, we also established the
average size of MVs to be 119.30 ± 8.61 nm (mean ± SEM) in
diameter in control cells and 140.40 ± 6.80 and 106.50 ± 6.07
(mean ± SEM) nm in CCL11 and TNF-α, respectively
(Figure 6A). Considering all conditions, eosinophil EV
diameters varied from 20 to 1000 nm, with most MVs showing
diameters between 20 and 200 nm (Figure 6B). MVs released
in response to TNF-α were significantly smaller compared to
FIGURE 4 | Proportion of eosinophils releasing MVs. (A) While just 50%
of unstimulated cells produced MVs, 90 and 100% of eosinophils formed MVs
in CCL11 and TNF-α-stimulated eosinophils, respectively. (B) Heterogeneity of
cell responses in unstimulated and stimulated eosinophils. In unstimulated
cells, most MV-producing cells (30%) released 1–3 MVs/cell section whereas
∼70% of cells produced 1–9 MVs and 4–21 MVs/cell section in response to
CCL11 and TNF-α stimulation, respectively. Counts were derived from three
experiments with a total of 516 MVs counted in 110 electron micrographs
randomly taken and showing the entire cell profile and nucleus.
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FIGURE 5 | Differential release of nascent MVs by human activated eosinophils. (A) A representative electron micrograph of a TNF-α-stimulated eosinophil
shows MVs in different steps of budding at cell surface (highlighted in blue, arrows) and secretory granules (Gr) exhibiting content losses in the cytoplasm. The MVs
indicated by the black arrows are seen in high magnification in (Ai) and (Aii). Note, that while (Ai) shows a MV in process of outward budding; (Aii) shows a free MV,
completely detached from the plasma membrane. (B) Illustration depicting the process of MV formation in human eosinophils as observed in the present work.
(C) Significant increases in numbers of budding MVs occurred after stimulation with CCL11 or TNF-α compared to unstimulated cells (****P < 0.0001). TNF-α elicited
higher numbers of MVs in process of budding compared to the CCL11 group (####P < 0.0001). Increase in numbers of free vesicles occurred after stimulation
with CCL11 compared to unstimulated cells (*P = 0.020). Eosinophils were isolated from the peripheral blood by negative selection, stimulated for 1 h, immediately
fixed in suspension and processed for conventional TEM. Counts were derived from three experiments, with a total of 516 MVs counted in 110 electron micrographs
randomly taken and showing the entire cell profile and nucleus (N).
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FIGURE 6 | Diameter of MVs produced by unstimulated and stimulated human eosinophils. (A) Determination of mean diameter of MVs. Significant decrease
in the diameters of released MVs occurred after stimulation with TNF-α compared to both unstimulated and CCL11-stimulated groups (****P < 0.0001). (B) The
percentages of MVs per diameter ranges are shown. Representative electron micrographs of MVs are seen within each diameter range. Diameters of MVs were
measured using Image J software and grouped in different ranges (20–100, 100–200, 200–300, 300–1000 nm). These analyses were done in clear cross-cell sections
exhibiting the entire eosinophil cell profile (n = 110 cells), intact plasma membranes, and nuclei.
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those released after CCL11 stimulation and by unstimulated cells
(P < 0.0001; Figures 6A,B).
Next, we investigated if the MVs produced by human
eosinophils expressed CD63 or CD9. Ultrastructural
immunolabeling for these tetraspanins were achieved with
pre-embedding immunonanogold EM, a technique that has
been used by us to ascertain precise localization of cytokines,
immune cell signaling molecules and tetraspanins in leukocytes
(Melo et al., 2014). In previous works, we have defined the
ultrastructural pattern of immunolabeling for these tetraspanins
in human eosinophils (Akuthota et al., 2012; Carmo et al.,
2016). While CD63 is consistently found intracellularly in
association with granules undergoing losses of their contents
and large vesicular carriers (Carmo et al., 2016), pools of CD9
are more detectable at the eosinophil surface (Akuthota et al.,
2012). In the present work, ultrastructural immunolabeling for
CD63 and CD9 at MVs was investigated for the first time. All
groups showed clear immunonanogold labeling for both CD63
(Figures 7A,C) and CD9 (Figure 7B). However, not all MVs
were positive (see, for example Figure 7Ci). In both unstimulated
and stimulated cells, immunolabeling for CD9 and CD63 were
found in around 50 and 15% of the MVs, respectively, regardless
of the stimulation condition.
Control cells, from all conditions, in which the primary
antibody was omitted or replaced by an irrelevant antibody were
negative (Supplementary Figure 4).
Annexin V Staining of Stimulated Human
Eosinophils
It is recognized that phosphatidylserine is relocated to the
outer membrane leaflet at sites on the cell surface where MV
shedding occurs (reviewed in Hugel et al., 2005; Muralidharan-
Chari et al., 2010). Then, we next stained eosinophils with
annexin-V-FITC and samples were analyzed by both flow
cytometry and confocal microscopy. Intact eosinophils
were gated and their representative histogram is shown in
Figures 8A,B, respectively. The histogram depicted unimodal
distribution indicating that most cells were negatively stained
by annexin-V. However, higher annexin-V intensities were
observed in CCL11 and TNF-α stimulated compared to
unstimulated eosinophils (Figure 8C). Confocal microscopy
analyses showed cell surface distribution of annexin-V with
suggestive images of MV formation in a population of stimulated
cells (Figure 8D). The absence of noticeable TUNEL positive
cells in CCL11 and TNF-α stimulated cells (Supplementary
Figure 5) as well as by TEM indicated these are not apoptotic
bodies.
DISCUSSION
The production of EVs during immune responses has
increasingly been demonstrated. These vesicles released by
cells from the immune system have been characterized as a
new mechanism of cell-to-cell communication and emerged
as potential mediators of the cell immune effects (reviewed in
Buzas et al., 2014; Colombo et al., 2014; Robbins and Morelli,
2014; Greening et al., 2015). Here, we identified, for the first
time, that human eosinophils release MVs in physiological
conditions and that these cells respond to the chemokine
CCL11 and the cytokine TNF-α stimuli with increased
formation of these plasma membrane-derived vesicles. We thus
recognized that, in addition to the secretory processes largely
described for human eosinophils (PMD, classical exocytosis
and cytolysis), these cells also have the competence to secrete
MVs and that these vesicles likely underlie eosinophil immune
responses.
The cell biology of EVs is still poorly understood. To
comprehend the origin of the different populations of these
secreted membrane-bound vesicles and their functional
significance, a better knowledge of their mechanisms of
biogenesis and secretion is still needed (Colombo et al., 2014).
Here we provided a comprehensive evaluation of EVs secreted
by human eosinophils using TEM, which is considered the gold
standard for EV visualization (Lawson et al., 2016). Our present
work highlights important aspects to the maturing field of EV
research. First, it is clear that EVs cannot be defined on the basis
of their size range as exosomes or MVs since these classes of EVs
have overlapping sizes. In general, exosomes are considered to
be smaller (∼50–100 nm) than MVs (reviewed in van der Pol
et al., 2012; Lawson et al., 2016), but we found that MVs from
eosinophils can be as small as 20 nm (range of 20–1000 nm),
with most MVs measuring 20–200 nm. In the literature, MVs
have been reported as a heterogeneous population in size up
to 2000 nm (reviewed in Buzas et al., 2014; Schwab et al., 2015;
Lawson et al., 2016). Because our electron microscopic analyses
were done on a population of MVs clearly seen at cell surface
(nascent MVs), when the cells were still in suspension, we believe
that the observed diameter range is more precise than those
established on isolated vesicles. Indeed, because of the small
size of MVs, a considerable portion of them may be below the
detection range of conventional detection methods (van der Pol
et al., 2012). Moreover, mechanical disruption of the cells/tissues
can interfere with the EV purity, since intracellular vesicles
might also be isolated during the process (Lötvall et al., 2014).
This is particularly concerning for human eosinophils, which
have a well-characterized intracellular morphologically distinct
vesicular system termed eosinophil sombrero vesicles (EoSVs;
150–300 nm diameter) that can be isolated and maintain their
integrity even after cell cytolysis (Melo et al., 2005b, 2008b,
2009; Saffari et al., 2014). Second, our findings demonstrate,
for the first time, that, depending on the influence of external
factors/stimuli, the sizes of MVs can vary (Figure 6). Thus,
MVs released from TNF-α-stimulated eosinophils exhibited
smaller size compared to CCL11-stimulated cells (Figure 6).
This might be explained by the rapid production of these
membranous structures after stimulation, which may be affecting
membrane replenishment and dynamics required for vesicle
formation.
The present work also raises discussion on an important
point of the EV biology: the use of appropriate markers for
EVs released by non-immune and immune cells. In general,
the tetraspanins CD63 and CD9 have been proposed as
“universal” EV markers and exosomes have been described
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FIGURE 7 | CD63 and CD9 immunolabeling of MVs by immunonanogold EM. (A–C) Representative electron micrographs of stimulated human eosinophils
showing the entire cell profile after CD63 (A,C) or CD9 (B) immunolabeling. Note that while CD63 is consistently found intracellularly in association with secretory
granules (Gr) as seen in (A) and (C), pools of CD9 are more detectable at the eosinophil surface as observed in (B). (Ai, Aii, Bi, Bii, Ci, Cii) CD63 and CD9-positive
MVs (arrows) are seen in higher magnification in the boxed areas. Note, that not all MVs were labeled. Eosinophils were isolated from the peripheral blood by negative
selection, stimulated for 1 h with CCL11 (A,B) or TNF-α (C), immediately fixed in suspension and processed for immunonanogold EM.
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FIGURE 8 | Annexin-V staining of human eosinophils. (A–C) Flow cytometric analyses show higher annexin-V intensities in CCL11 and TNF-α-stimulated
compared to unstimulated cells. (D) Representative confocal microscopic image from a CCL11-stimulated eosinophil reveal cell surface distribution of annexin-V.
Arrows indicate suggestive images of MV formation. Eosinophils were isolated from the peripheral blood by negative selection, stimulated for 1 h with CCL11 or TNF-α
and stained with annexin-V.
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as highly enriched in these molecules (reviewed in Andreu
and Yáñez-Mó, 2014). However, the presence of CD63 and
CD9 in plasma membrane-derived MVs has been much less
studied, regardless of cell type. Few studies have currently
assumed that MVs express tetraspanins (Crescitelli et al., 2013).
Here, we provide direct evidence for both CD63 and CD9
localization on MVs secreted by human eosinophils (Figure 7).
Our immunonanogold EM findings clearly showed CD63 and
CD9 labeling associated with the delimiting membrane of
MVs (Figure 7). However, in accord with our nanoscale flow
cytometry results (Figure 2), immunoEM also revealed that
not all MVs were labeled (see, for example, Figure 7Ci), with
∼50 and ∼15% of these vesicles labeled for CD9 and CD63,
respectively, regardless of whether cells were stimulated or not.
CD63 was not detected by flow cytometry, possibly because of
the very small size and/or low proportion of this CD63-positive
EV population. Therefore, CD9, a tetraspanin largely found at
the surface of human eosinophils (Akuthota et al., 2012) might
be a better marker than CD63 for MVs released by human
eosinophils.
At first view it seems unexpected to have undetectable
levels (as observed by flow cytomety) or low labeling (as
seen by immunoEM) for CD63 on MVs. However, we have
demonstrated in a recent study by different approaches that
while CD63 is observed at the eosinophil’s cell surface after
stimulation with both CCL11 and TNF-α, a robust pool of
CD63 remains in the cytoplasm in association with secretory
granules and EoSVs, with no detectable difference in the CD63
total content when unstimulated and stimulated cells were
compared (Carmo et al., 2016). This means that CD63 is
present, as a preformed pool within eosinophils and that most
of this internal CD63 pool is not completely externalized in
response to stimulation (Carmo et al., 2016). Accordingly, a
small proportion of secreted MVs showed immunolabeling for
this tetraspanin. Moreover, our comprehensive EM analyses
demonstrated that eosinophils release MVs and not typical
exosomes in response to stimulation with CCL11 or TNF-α.
Although MVBs were observed in the eosinophil cytoplasm
during the present EM analyses, there was no ultrastructural
evidence for exosome secretion. Our data are in part in accord
with a work showing that stimulation of human eosinophils
with CCL11 does not appear to increase secretion of CD63-
positive exosomes (Mazzeo et al., 2015). On the other hand,
these authors found that stimulation with interferon-gamma
(INF-γ) induced exosome secretion by these cells (Mazzeo et al.,
2015).
Here, induction of EV release was achieved with TNF-α and
CCL11. TNF-α is a potent cytokine that mediates inflammatory
responses and innate immunity (reviewed in Sabio and Davis,
2014). Stimulation of human eosinophils with TNF-α induces
secretion of IL-4, IL-6 and INF-γ (Spencer et al., 2009).
TNF-α is also central for INF-γ-induced secretion of Th1-type
chemokines and to enhance IL-4-induced secretion of Th2-
type chemokines by human eosinophils (Liu et al., 2007). We
recently demonstrated that this stimulus leads to a secretory
process characterized by fusion of eosinophil secretory granules
(classical exocytosis) and extensive release of granule contents
while CCL11 elicits a progressive and more subtle release
of specific products stored in secretory granules (piecemeal
degranulation; Carmo et al., 2016). For example, CCL11
stimulation of human eosinophils elicits specific release of IL-
4 (Bandeira-Melo et al., 2001). Our present data showed that
the differential secretory/immune responses induced by these
two stimuli trigger differential rates of EV release. Higher
numbers of MVs were detected in eosinophils in response to
TNF-α compared to CCL11 stimulation. Thus, MVs released
by human eosinophils may potentially carry different cargos
and mediate different effects on other cells, depending on
the stimulus/pathological condition. We can speculate that
eosinophil MVs might be acting as potential mediators of
immune responses. The release of them at inflammatory sites
in tissues and/or in biological fluids, including peripheral blood,
may enable in situ and/or long-distance transfer of bioactive
molecules such as cytokines. These molecules may influence
target cells by activating cell receptors with vital roles in
inflammation. In fact, the implication of MVs in inflammation
has been documented. For example, the presence of interleukin-
1β was detected in MVs shedding from the plasma membrane
of activates monocytes (MacKenzie et al., 2001). However,
the identification of molecular cargos within these eosinophil-
released MVs awaits further investigation to get insights into
their functional roles.
Taken together, our findings identify, for the first time, that
human eosinophils secrete MVs during physiological conditions
and that the release of these vesicles is increased in response
to both CCL11 and TNF-α. Given the potential of EVs as
mediators of immune responses, our results open new venues to
understand how these vesicles function to regulate eosinophil-
mediated immunity and if they can be used as biomarkers for
eosinophil-associated disorders.
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